Month: September 2026

Marimekko Corporation, Stock Exchange Release, 25 September 2026 at 6.45 p.m. EEST

Marimekko Corporation: Repurchase of own shares during week 39/2026

Marimekko Corporation has acquired its own shares during week 39 in the Helsinki Stock Exchange as follows:

Trade date	Shares	Average price / share	Total cost
21.9.2026	12,700	9.5713	121,555.51
22.9.2026	12,442	9.6475	120,034.20
23.9.2026	11,788	9.6018	113,186.02
24.9.2026	12,296	9.5415	117,322.28
25.9.2026	13,800	9.5130	131,279.40
Total amount, week 39	63,026	9.5735	603,377.41

Marimekko Corporation now holds a total of 196,486 shares including the shares repurchased on 25 September 2026.       

On 14 September 2026, Marimekko announced that it will start acquiring the company’s own shares based on the authorization granted by the Annual General Meeting held on 16 April 2026. The repurchase of own shares is executed in compliance with Regulation No. 596/2014 of the European Parliament and Council (MAR) Article 5 and the Commission Delegated Regulation (EU) 2016/1052.

Details of the transactions are included as an appendix of this announcement.

On behalf of Marimekko Corporation
EVLI OYJ
Aleksi Jalava

Further information:
Anna Tuominen
tel. +358 40 584 6944
anna.tuominen@marimekko.com

DISTRIBUTION:
Nasdaq Helsinki Ltd
Key media

Attachment

• MEKKO_Trades_Week_39.xlsx

Press release  –  Regulated information

Brussels, September 25, 2026, 17:45 CEST

In line with Belgian transparency legislation (Law of May 2, 2007), Citigroup Inc. recently sent to Solvay the following transparency notification indicating that they crossed the threshold of 3%.

Here is a summary of the notification:

Date on which the threshold is crossed	Voting rights after the transaction	Equivalent financial instruments after the transaction	Total
September 21, 2026	–	–	–

The notification, dated September 22, 2026, contains the following information:

• Reason for the notification:
  • Acquisition or disposal of voting securities or voting rights
  • Downward crossing of the lowest threshold
• Notified by: A parent undertaking or a controlling person
• Date on which the threshold is crossed: September 21, 2026
• Threshold of direct voting rights crossed: 3% downwards
• Denominator: 105,876,416
• Persons subject to the notification requirement: Citigroup Inc., 1209 North Orange Street in Wilmington, Delaware 19801, USA

Transparency notifications and the full chain of controlled undertakings through which the holding is effectively held are available on the Investor Relations Section of Solvay’s website.

Contacts

Investor relations

Geoffroy d’Oultremont: +32 478 88 32 96
Vincent Toussaint: +33 6 74 87 85 65
Charlotte Vandevenne: +32 471 68 01 66
investor.relations@solvay.com

Media relations

Peter Boelaert: +32 479 30 91 59
Laetitia Van Minnenbruggen: +32 484 65 30 47
media.relations@solvay.com

About Solvay 

Solvay, a pioneering chemical company with a legacy rooted in founder Ernest Solvay’s pivotal innovations in the soda ash process, is dedicated to delivering essential solutions globally through its workforce of around 8,400 employees. Since 1863, Solvay harnesses the power of chemistry to create innovative, sustainable solutions that answer the world’s most essential needs such as purifying the air we breathe and the water we drink, preserving our food supplies, protecting our health and well-being, creating eco-friendly clothing, making the tires of our cars more sustainable and cleaning and protecting our homes. Solvay’s unwavering commitment drives the transition to a carbon-neutral future by 2050, underscoring its dedication to sustainability and a fair and just transition. As a world-leading company with €4.3 billion in net sales in 2025, Solvay is listed on Euronext Brussels and Paris (SOLB). For more information about Solvay, please visit solvay.com or follow Solvay on Linkedin.

Ce communiqué de presse est également disponible en français.
Dit persbericht is ook in het Nederlands beschikbaar.

Attachments

• 20260922 – Notification Citi
• Press release

Ad hoc announcement pursuant to Art. 53 LR

U.S. clinical hold remains in place; study continues in all other countries

Company initiates expansion of clinical sites and enrollment in Europe, Asia and Latin America

Topline data from ENIGMA-TRS 1 expected in Q1 2027

MILAN and MORRISTOWN, N.J., Sept. 25, 2026 (GLOBE NEWSWIRE) — Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system, today announced that it has been informed by the U.S. Food and Drug Administration (FDA) that the hold on the enrollment of new patients will remain in place at U.S. sites in the Phase 3 ENIGMA-TRS 2 study with evenamide. Enrollment in the study continues outside the U.S. Newron anticipates receiving a written communication from the FDA with additional information regarding its decision and any further potential protocol changes that may be required to lift the hold.

Evenamide targets the modulation of excessive release of glutamate in patients suffering from treatment-resistant schizophrenia (TRS).

Newron is initiating the expansion of clinical sites and enrollment for ENIGMA-TRS 2 in Europe, Asia and Latin America. To date, approximately 80 patients have entered screening. The study is expected to enroll at least 400 patients following successful completion of the 42-day screening period.

The ENIGMA-TRS 1 study is currently ongoing in 20 countries, with ENIGMA-TRS 2 ongoing in four countries.

“Newron is highly confident in the significant body of clinical and preclinical safety data for evenamide, and we will continue to work constructively with the FDA to address the clinical hold,” said Ravi Anand, Chief Medical Officer of Newron.

About ENIGMA-TRS

ENIGMA-TRS 1 is an ongoing, international, 52-week, randomized, double-blind, placebo-controlled Phase 3 study evaluating the efficacy, tolerability, and safety of the 15mg BID and 30mg BID therapeutic doses of evenamide compared to placebo. Patients on second-generation antipsychotics, including clozapine, will meet Treatment Response and Resistance Psychosis international consensus criteria for TRS. The study is expected to have enrolled at least 600 patients in the study by mid-October 2026, at study centers in 20 countries in Europe, Asia, Latin America, and Canada.

The primary assessment of efficacy and safety of ENIGMA-TRS 1 will be performed 12 weeks after randomization to treatment. Following this initial period, the study will continue to be double-blind and placebo-controlled until the 26- and 52-week time points. The primary efficacy endpoint of the trial will be the change from baseline in the Positive and Negative Syndrome Scale (PANSS) scores at 12 weeks. Newron expects to announce results from the 12-week primary endpoint assessment in Q1 2027.

ENIGMA-TRS 2 is taking place at centers in the U.S. and selected additional countries with the same screening procedure as the ENIGMA-TRS 1 trial. ENIGMA-TRS 2 will include at least 400 patients in a 12-week, randomized, double-blind, placebo-controlled Phase 3 study, designed to evaluate the efficacy, tolerability, and safety of the 15mg BID dose of evenamide compared to placebo. In December 2025, ENIGMA-TRS 2 was initiated in the U.S., following approvals from the U.S, Food and Drug Administration (FDA) and the Institutional Review Board (IRB). The efficacy and safety analysis will be performed at the 12-week point following successful completion of the study. On April 29, 2026, Newron reported a hold by the FDA on the enrollment of new patients in the U.S. sites of the study, following Newron’s notification to the agency of the sudden unexpected death of a study participant at a clinical site outside the United States. The investigator assessed the event as unrelated to study treatment. Newron has informed the independent international safety monitoring board for the overall ENIGMA-TRS program, which has reviewed the event and recommended that the studies continue as designed. While U.S. patients entered screening, no U.S. patients have been dosed with evenamide, in the study.

About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of innovative therapies for patients with diseases of the central and peripheral nervous system. Headquartered in Bresso near Milan, Italy, the Company has a strong track record of advancing neuroscience-based treatments from discovery to market. Newron’s lead compound, evenamide, is a first-in-class glutamate modulator and has the potential to be the first add-on therapy for treatment-resistant schizophrenia (TRS) and for poorly responding patients with schizophrenia. Evenamide is currently developed in the global pivotal ENIGMA-TRS Phase 3 development program. Clinical trial results to date demonstrate the benefits of this drug candidate in TRS as well as poorly responding patient population, with significant improvements across key efficacy measures increasing over time, as well as a favorable safety profile, which is uncommon for available antipsychotic medications. Newron has signed development and commercialization agreements for evenamide with EA Pharma (a subsidiary of Eisai) for Japan and other Asian territories, as well as Myung In Pharm for South Korea. Newron’s first marketed product, Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea. The product is commercialized by Newron’s partner Zambon, with Supernus Pharmaceuticals holding marketing rights in the U.S., and Meiji Seika responsible for development and commercialization in Japan and other key Asian territories. For more information, please visit: https://www.newron.com and connect with us on LinkedIn.

For more information, please contact:

Newron
Stefan Weber – CEO; +39 02 6103 46 26, pr@newron.com

UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins, FTI Consulting; +44 20 3727 1000, SCnewron@fticonsulting.com   

Switzerland
Valentin Handschin, IRF; +41 43 244 81 54, handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke / Maximilian Schur, MC Services; +49 211 52925227, newron@mc-services.eu

USA
John Fraunces, LifeSci Advisors; +1 917 355 2395, jfraunces@lifesciadvisors.com

Important Notices
This document contains forward-looking statements, including (without limitation) about (1) Newron’s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron’s strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron’s research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange or the Dusseldorf Stock Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.

Amsterdam, 25 September 2026 — AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) has published an Annex IX information document in connection with the secondary listing of its shares on the Frankfurt Stock Exchange pursuant to Article 1(5)(ba) of Regulation (EU) 2017/1129 (the Prospectus Regulation). The intention to apply for the listing on the Frankfurt Stock Exchange was announced on August 24, 2026.

The first day of trading on the Frankfurt Stock Exchange is expected to be September 30, 2026. The AMG shares will trade on the Frankfurt Stock Exchange under the ticker symbol “ADG”. As previously announced, AMG does not plan to issue or offer any new shares in connection with the secondary listing in Frankfurt. Euronext Amsterdam will continue to be AMG’s primary listing.

The Annex IX information document was also filed with the Dutch Authority for the Financial Markets (Stichting Autoriteit Financiële Markten) as competent authority under the Prospectus Regulation.

About AMG

AMG’s mission is to provide critical materials and related process technologies to advance a less carbon-intensive world. To this end, AMG is focused on the production and development of energy storage materials such as lithium, vanadium, and tantalum. In addition, AMG’s products include highly engineered systems to reduce CO₂ in aerospace engines, as well as critical materials addressing CO₂ reduction in a variety of other end use markets.

AMG’s Lithium segment spans the lithium value chain, reducing the CO₂ footprint of both suppliers and customers. AMG’s Vanadium segment is the world’s market leader in recycling vanadium from oil refining residues, spanning the Company’s vanadium, molybdenum, titanium, and chrome businesses. AMG’s Technologies segment is the established world market leader in advanced metallurgy and provides equipment engineering to the aerospace engine sector globally. It serves as the engineering home for the Company’s fast-growing LIVA batteries, NewMOX SAS formed to span the nuclear fuel market, and AMG’s mineral processing operations in antimony.

With approximately 3,500 employees, AMG operates globally with production facilities in Germany, the United Kingdom, France, the United States, China, Mexico, Brazil, and India, and has sales and customer service offices in Japan (www.amg-nv.com).

For further information, please contact:
AMG Critical Materials N.V.        +49 176 1000 73 14
Thomas Swoboda
tswoboda@amg-nv.com

Disclaimer

Certain statements in this press release are not historical facts and are “forward looking.” Forward looking statements include statements concerning AMG’s plans, expectations, projections, objectives, targets, goals, strategies, future events, future revenues or performance, capital expenditures, financing needs, plans and intentions relating to acquisitions, AMG’s competitive strengths and weaknesses, plans or goals relating to forecasted production, reserves, financial position and future operations and development, AMG’s business strategy and the trends AMG anticipates in the industries and the political and legal environment in which it operates and other information that is not historical information. When used in this press release, the words “expects,” “believes,” “anticipates,” “plans,” “may,” “will,” “should,” and similar expressions, and the negatives thereof, are intended to identify forward looking statements. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general and specific, and risks exist that the predictions, forecasts, projections and other forward-looking statements will not be achieved. These forward-looking statements speak only as of the date of this press release. AMG expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained herein to reflect any change in AMG’s expectations with regard thereto or any change in events, conditions, or circumstances on which any forward-looking statement is based.

Attachment

• Annex IX Information Document Press Release

Palm Beach, FL, Sept. 25, 2026 (GLOBE NEWSWIRE) — Pinnacle Acquisition Corporation (NYSE: PNAQ.U) (the “Company”) announced today that, commencing September 25, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and rights included in the units. The Class A ordinary shares and rights that are separated will trade on the New York Stock Exchange under the symbols “PNAQ” and “PNAQ.RT,” respectively. Those units not separated will continue to trade on the New York Stock Exchange under the symbol “PNAQ.U.”

“We believe our team’s experience building and scaling public-market platforms, executing strategic M&A and working across commercial and consumer finance positions us well to identify an exceptional company and help accelerate its next stage of growth,” said Steve Hudson, Co-founder, Chief Executive Officer and Chairman of Pinnacle Acquisition Corporation.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Pinnacle Acquisition Corporation

Pinnacle Acquisition Corporation is a blank check company, also commonly referred to as a special purpose acquisition company, or SPAC, incorporated as a Cayman Islands exempted company and formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

The Company intends to focus its search on partnering with management and owners of high-quality companies seeking an alternative to a traditional initial public offering in commercial finance, consumer finance and adjacent areas of the broader financial services ecosystem, including technology-enabled platforms and specialty finance businesses.

Pinnacle will seek to leverage its leadership team’s operating, M&A and capital markets experience, as well as its relationships with strategic acquirers, financial sponsors, investors and sector participants. The Company believes the current market environment, including growth in commercial and consumer finance, the importance of scaled specialty finance platforms and the shift toward diversified lending models, is creating attractive opportunities for partnership and value creation.

“Pinnacle was designed to bring experienced sponsorship, disciplined acquisition criteria and a partnership-oriented approach to companies that are ready for the public markets,” said Andrew Rechtschaffen, Co-founder and Director of Pinnacle Acquisition Corporation. “We currently see a compelling universe of potential opportunities across financial services and related technology-enabled sectors, and we are focused on finding a business where our team can help accelerate long-term value creation following the IPO.”

While the Company may pursue a business combination in any business or industry, it intends to focus its efforts on businesses with growth platforms, strong management teams and opportunities to drive value creation such as the ability to pursue further accretive acquisitions or capital structure optimization that can benefit from the business expertise of its Chief Executive Officer and Chairman, Steven K. Hudson, and its Chief Financial Officer, Jack Schneider. Andrew Rechtschaffen, Paul Stoyan, Karen Martin and Harry Brandler also serve as board members.

Forward-Looking Statements

This press release may include, and oral statements made from time to time by representatives of the Company may include, “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements regarding possible business combinations and the financing thereof, and related matters, as well as all other statements other than statements of historical fact included in this press release are forward-looking statements. When used in this press release, words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “would” and similar expressions, as they relate to the Company or its management team, identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, the Company’s management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors detailed in the Company’s filings with the Securities and Exchange Commission (“SEC”). All subsequent written or oral forward-looking statements attributable to the Company or persons acting on its behalf are qualified in their entirety by this paragraph. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and prospectus for the Company’s initial public offering filed with the SEC. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Company Contact

Jack Schneider
Chief Financial Officer
(561) 309-3447